ID: h-9cd3aac2
Hypothesis
CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Efflux and Reduce Aβ Production
CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Efflux and Reduce Aβ Production.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Efflux and Reduce Aβ Production
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["CYP46A1/Cholesterol 24-Hydroxylase<br/>Neuronal Cholesterol Turnover"]
B["24S-Hydroxycholesterol Output<br/>Cholesterol Efflux Signal"]
C["LXR/ABCA1 Activation<br/>Membrane Lipid Homeostasis"]
D["Amyloidogenic APP Processing Falls<br/>BACE1 Access Reduced"]
E["Synaptic Membrane Fluidity Restored<br/>Receptor Trafficking Stabilized"]
F["Lower A-beta Burden<br/>Neuronal Function Preserved"]
A --> B
B --> C
C --> D
C --> E
D --> F
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Supports
CYP46A1 expression is reduced in AD hippocampus, correlating with increased amyloid burden
Supports
Genetic knockdown of CYP46A1 in 3xTg-AD mice increases Aβ accumulation and worsens cognitive deficits
Supports
Patent landscape is largely unencumbered for CNS applications
Expert assessment
Contradicts
CYP46A1 reduction in AD hippocampus could represent compensatory downregulation in response to already-elevated 24-HC
Skeptic critique
Contradicts
24-HC exhibits biphasic dose-response: moderate concentrations are neuroprotective, elevated 24-HC promotes neuronal apoptosis
Contradicts
Cholesterol reduction itself increases BACE1 expression through SREBP2 activation
Contradicts
Efavirenz carries FDA black box for psychiatric reactions—neurotoxicity confounds cognitive benefits
Expert assessment
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CYP46A1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CYP46A1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CYP46A1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0047
Events (7d)
1
Price History
▼3.4%💾 Resource Usage
LLM Tokens
38,938
$0.1168
Total Cost
$0.1168
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we apply CRISPR-activation of CYP46A1 in primary cultured neurons derived from 3xTg-AD mice, THEN intracellular cholesterol will decrease by ≥40% and extracellular 24-hydroxycholesterol will increa | Intracellular cholesterol (measured by filipin staining and quantitative fluorescence microscopy) will be reduced by ≥40%, while conditioned medium 24-HC (LC-MS | — no observation — | pending | 0.55 |
| IF we administer a CYP46A1 activator (efavirenz at 10 mg/kg/day, a dose shown to cross the blood-brain barrier) to APP/PS1 transgenic mice for 8 weeks beginning at 6 months of age, THEN hippocampal Aβ | Hippocampal Aβ42 levels will be reduced by ≥30% (measurable by ELISA), with corresponding increase in plasma 24-hydroxycholesterol as a proxy for CYP46A1 activa | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we administer a CYP46A1 activator (efavirenz at 10 mg/kg/day, a dose shown to cross the blood-brain barrier) to APP/PS1 transgenic mice for 8 weeks beginning at 6 months of age, THEN hippocampal Aβ42 concentrations will decrease by at least 30% compared to vehicle-treated controls.
Predicted outcome: Hippocampal Aβ42 levels will be reduced by ≥30% (measurable by ELISA), with corresponding increase in plasma 24-hydroxycholesterol as a proxy for CYP4
Falsification: If hippocampal Aβ42 levels show no statistically significant reduction (p ≥ 0.05) or increase in 24-HC is not observed, the therapeutic mechanism is not supported.
pendingconf 55%
IF we apply CRISPR-activation of CYP46A1 in primary cultured neurons derived from 3xTg-AD mice, THEN intracellular cholesterol will decrease by ≥40% and extracellular 24-hydroxycholesterol will increase by ≥50% within 72 hours post-transduction.
Predicted outcome: Intracellular cholesterol (measured by filipin staining and quantitative fluorescence microscopy) will be reduced by ≥40%, while conditioned medium 24
Falsification: If intracellular cholesterol does not decrease significantly or extracellular 24-HC does not increase, CYP46A1 activation is insufficient to alter neuronal cholesterol homeostasis.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.